Neoadjuvant Chemotherapy Versus Primary Cytoreductive Surgery for Metastatic Endometrial Cancer.

ABSTRACT:

Objective

To evaluate the pattern of use and clinical outcomes associated with neoadjuvant chemotherapy (NACT) compared with primary debulking surgery (PDS) in patients with stage IV endometrial cancer.

Methods

We utilized the National Cancer Database to identify individuals diagnosed with stage IV endometrial cancer, and categorized them according to receipt of NACT or PDS. Propensity score weighting using inverse probability of treatment weighting was applied. Survival outcomes were evaluated using both an intention-to-treat (ITT) analysis, which included all eligible patients, and a per-protocol (PP) analysis restricted to those who underwent chemotherapy and surgery.

Results

Among 18,205 patients, NACT utilization rose from 30.3% in 2010 to 73.8% in 2021 (p < 0.00

SUBMITTER: Sassine D 

PROVIDER: S-EPMC12819165 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature